Amyotrophic lateral sclerosis (ALS) is a degenerative motor neuron disorder that leads to progressive muscle wasting and weakness. The typical survival time is three to five years from onset. The…
Although the malignant melanoma market has become increasingly crowded, an evolving trend of combining drug classes to create novel therapies is expanding treatment options for patients. While both…
As part of ongoing efforts to address the rising cost of pharmaceuticals, the U.S. Centers for Medicare & Medicaid Services significantly shifted policy to allow Medicare Advantage plans to impose…
As part of ongoing efforts to address the rising cost of pharmaceuticals, the U.S. Centers for Medicare & Medicaid Services significantly shifted policy to allow Medicare Advantage plans to impose…
Recent European approval of three anti-CGRP-targeted MAbs—Aimovig (Novartis), Ajovy (Teva) and Emgality (Eli Lilly)—together with the expected market penetration of the fourth anti-CGRP-…
Myelofibrosis (MF) is a hematological malignancy characterized by the disrupted production of blood cells and bone marrow scarring; symptoms include severe anemia, weakness, fatigue, and…
MARKET OUTLOOK Non-small cell lung cancer (NSCLC) is one of the most commonly diagnosed cancers and the leading cause of cancer-related deaths in China. NSCLC has one of the most dynamic drug…
MARKET OUTLOOKSuccessive label expansions in the multiple myeloma treatment landscape are driving significant commercial reward for some well-entrenched current therapies. With Celgene’s Revlimid…
MARKET OVERVIEWHidradenitis suppurativa (HS) is a chronic relapsing inflammatory disorder affecting hair follicles. Humira is the only FDA-approved therapy for the disease; its use is limited—…
Biologics approved to treat immune indications (e.g., rheumatoid arthritis, Crohn’s disease) are among the most commercially successful biopharmaceutical products and offer a great opportunity…
The ulcerative colitis (UC) market is expected to grow steadily over the next decade. The entry of first-in-UC oral therapies (e.g., Pfizer’s Xeljanz) for the moderate to severe population,…
The Alzheimer’s disease (AD) market comprises a handful of symptomatic options that offer modest efficacy for a limited duration, leaving wide open the opportunity for more-effective alternatives…
In July 2019, Amgen’s Kanjinti (trastuzumab biosimilar) and Mvasi (bevacizumab biosimilar) were the first monoclonal antibody (MAb) biosimilars launched in the United States. Between mid-…
MARKET OUTLOOKNon-small-cell lung cancer (NSCLC) has a high incidence and a large number of premium-priced therapies, which results in a significant financial burden on payers. Costs are set to…
The launch of several novel therapies, as well as multiple label expansions of premium-priced agents, will fuel significant growth of the non-Hodgkin’s lymphoma (NHL) therapy market over the ten-…